Mepolizumab Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 100 mg/1 mL

Reference Brands: Nucala (USA/EU)

Category: Respiratory Disorder

Mepolizumab is available in injection (prefilled syringe) and strengths such as 100 mg/1 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Mepolizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Mepolizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Mepolizumab, marketed under the brand name Nucala, is a humanized monoclonal antibody approved for the treatment of severe eosinophilic asthma. It is indicated as a maintenance therapy for patients aged six years and older who have an eosinophilic phenotype, in combination with other standard asthma medications. In the European Union, mepolizumab is approved as an add-on therapy for adults with severe refractory eosinophilic asthma. The medication works by targeting interleukin-5 (IL-5), a key cytokine responsible for the growth, activation, and survival of eosinophils, which are immune cells that contribute to airway inflammation. By inhibiting IL-5, mepolizumab reduces eosinophil levels, leading to decreased airway inflammation and fewer asthma exacerbations. Clinical studies have demonstrated that mepolizumab significantly lowers the risk of asthma-related hospitalizations and emergency interventions compared to placebo. The drug is administered as a 100 mg subcutaneous injection, typically once every four weeks, using a pre-filled syringe or auto-injector. Mepolizumab is generally well tolerated, with a favorable safety profile, and provides an effective therapeutic option for patients with severe eosinophilic asthma seeking improved disease control and quality of life.